Chengdu Easton Biopharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Chengdu Easton Biopharmaceuticals has a total shareholder equity of CN¥2.7B and total debt of CN¥167.0M, which brings its debt-to-equity ratio to 6.2%. Its total assets and total liabilities are CN¥3.4B and CN¥741.2M respectively. Chengdu Easton Biopharmaceuticals's EBIT is CN¥180.3M making its interest coverage ratio -10.8. It has cash and short-term investments of CN¥1.4B.
Key information
6.2%
Debt to equity ratio
CN¥166.99m
Debt
| Interest coverage ratio | -10.8x |
| Cash | CN¥1.41b |
| Equity | CN¥2.68b |
| Total liabilities | CN¥741.20m |
| Total assets | CN¥3.42b |
Recent financial health updates
No updates
Recent updates
Concerns Surrounding Chengdu Easton Biopharmaceuticals' (SHSE:688513) Performance
Nov 01
There Is A Reason Chengdu Easton Biopharmaceuticals Co., Ltd.'s (SHSE:688513) Price Is Undemanding
Jul 23Why Chengdu Easton Biopharmaceuticals' (SHSE:688513) Shaky Earnings Are Just The Beginning Of Its Problems
May 01Chengdu Easton Biopharmaceuticals Co., Ltd.'s (SHSE:688513) Share Price Matching Investor Opinion
Mar 26Financial Position Analysis
Short Term Liabilities: 688513's short term assets (CN¥1.9B) exceed its short term liabilities (CN¥662.6M).
Long Term Liabilities: 688513's short term assets (CN¥1.9B) exceed its long term liabilities (CN¥78.6M).
Debt to Equity History and Analysis
Debt Level: 688513 has more cash than its total debt.
Reducing Debt: 688513's debt to equity ratio has increased from 0.5% to 6.2% over the past 5 years.
Debt Coverage: 688513's debt is well covered by operating cash flow (134.2%).
Interest Coverage: 688513 earns more interest than it pays, so coverage of interest payments is not a concern.